NEWS ALERT SIGNUP STAY IN TOUCH HOME OUR COMPANY PRODUCT PORTFOLIO INVESTORS PRESS RELEASES CAREERS CONTACT Committed to addressing unmet medical needs through reinventing existing medications Changing therapy outcomes and improving the lives of patients around the globe. Our strategy: Providing relevant improvements Our development strategy of reformulating and repurposing approved pharmaceuticals primarily utilises the 505(b)(2) regulatory pathway in the U.S. and similar pathways in other countries, which are specifically designed for pharmaceutical agents for which the safety and efficacy have already been established. This focused strategy can dramatically reduce the clinical burden required to bring a product to market, and significantly shortens the development timelines while also reducing costs and risks. To achieve our goal of becoming a leader in the number of 505(b)(2) value-added products in development, we are in continuous dialogue with healthcare professionals, patient groups, payors and partners as well as leveraging our extensive sourcing network and R&D capabilities. We have adopted a flexible go-to-market strategy and believe we will be able to commercialise our cardiovascular portfolio in a cost-efficient manner with our own small, specialist sales force in the U.S. targeting hospital-based cardiologists. For our other product candidates, we intend to remain flexible and assess the optimal commercialisation strategy on a case-by-case basis to maximise the return on investment, including potential commercial opportunities outside the U.S. We develop products that offer clear benefits to patients, physicians and payors Faster innovation at a much lower cost Partnering opportunities: Together we can make a difference We work together with our partners to innovate and reinvent well-established medications to deliver timely and effective solutions to unmet medical needs and dramatically improve the lives of patients. As we continue to expand our product pipeline across various indications and stages of development, our team continuously evaluates co-development and in-licensing opportunities with the goal to bring much needed innovation to patients, healthcare professionals and payors. We are highly motivated to build strategic collaborations and establish productive commercial partnerships to bring our value-added products to market and look forward to working with you to build a better tomorrow. Contact us at businessdevelopment@hyloris.com Hyloris Pharmaceuticals SA HQ: Boulevard Gustave Kleyer 17, 4000 Liège, Belgium T:+32 (0)4 346 02 07 E:contact@hyloris.com Quick links HOME INVESTORS OUR STRATEGY PRODUCT PORTFOLIO OUR COMPANY PRESS RELEASES CAREERS CONTACT News alert signup Stay updated on the latest developments at Hyloris. NEWS VIA EMAIL 2021 - Hyloris Pharmaceuticals SA - Design & Development by CLICK GDPR - Privacy Policy GDPR - Cookies Policy Terms of website use We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent. Cookie Settings Accept All